Abstract The β-galactoside α2-6-sialyltransferase 1 (ST6Gal-I) is the principal
sialyltransferase responsible for the addition of α2-6-sialic acid to the termini N-glycans on …

The aberrant expression of sialyltransferase has a role in cell differentiation, neoplastic
transformation and the progression of various types of cancer. Our previous studies have …

Emerging evidence indicates that β-galactoside-α2, 3-sialyltransferase III (ST3Gal3)
involves in development, inflammation, neoplastic transformation, and metastasis. However …

Sialyltransferases transfer sialic acid to nascent oligosaccharides and are upregulated in
cancer. The inhibition of sialyltransferases is emerging as a potential strategy to prevent …

Altered glycosylation is a common feature of cancer cells and plays an important role in
tumor progression. β-Galactoside α2-6-sialyltransferase 1 (ST6Gal-I) is the critical …

Abnormal sialylation due to overexpression of sialyltransferases has been associated with
tumorigenesis and tumor progression. Although ST6Gal-I influences cancer persistence and …

Abstract Background Sialyltransferase I (ST6Gal-I) is an enzyme involved in tumor
metastasis that processes sialic acid precursors into their mature form, enabling them to …

The poor prognosis of hepatocellular carcinoma (HCC) is mainly because of its high rate of
metastasis. Thus, elucidation of the molecular mechanisms underlying HCC metastasis is of …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor
prognosis. Gemcitabine, as a single agent or in combination therapy, remains the frontline …

Purpose Excessive ST3Gal-I levels predict a poor outcome for patients with several types of
tumors. This study aims to investigate the role of ST3Gal-I in determining the invasive and …